Elucidating the Potential Inhibitor against Type 2 Diabetes Mellitus Associated Gene of GLUT4

被引:2
|
作者
Aldahish, Afaf [1 ]
Balaji, Prasanalakshmi [2 ]
Vasudevan, Rajalakshimi [1 ]
Kandasamy, Geetha [3 ]
James, Jainey P. [4 ]
Prabahar, Kousalya [5 ]
机构
[1] King Khalid Univ, Coll Pharm, Dept Pharmacol, Abha 61421, Saudi Arabia
[2] King Khalid Univ, Dept Comp Sci, Abha 61421, Saudi Arabia
[3] King Khalid Univ, Coll Pharm, Dept Clin Pharm, Abha 62529, Saudi Arabia
[4] Nitte, NGSM Inst Pharmaceut Sci NGSMIPS, Dept Pharmaceut Chem, Mangaluru 575018, Karnataka, India
[5] Univ Tabuk, Fac Pharm, Dept Pharm Practice, Tabuk 71491, Saudi Arabia
来源
JOURNAL OF PERSONALIZED MEDICINE | 2023年 / 13卷 / 04期
关键词
T2DM; GLUT4; ADMET; CoFACTOR; ChEMBL; MOE; PERMEABILITY; PATHOGENESIS; INFLAMMATION; ABSORPTION; DRUGS; TOOL;
D O I
10.3390/jpm13040660
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Diabetes is a chronic hyperglycemic disorder that leads to a group of metabolic diseases. This condition of chronic hyperglycemia is caused by abnormal insulin levels. The impact of hyperglycemia on the human vascular tree is the leading cause of disease and death in type 1 and type 2 diabetes. People with type 2 diabetes mellitus (T2DM) have abnormal secretion as well as the action of insulin. Type 2 (non-insulin-dependent) diabetes is caused by a combination of genetic factors associated with decreased insulin production, insulin resistance, and environmental conditions. These conditions include overeating, lack of exercise, obesity, and aging. Glucose transport limits the rate of dietary glucose used by fat and muscle. The glucose transporter GLUT4 is kept intracellular and sorted dynamically, and GLUT4 translocation or insulin-regulated vesicular traffic distributes it to the plasma membrane. Different chemical compounds have antidiabetic properties. The complexity, metabolism, digestion, and interaction of these chemical compounds make it difficult to understand and apply them to reduce chronic inflammation and thus prevent chronic disease. In this study, we have applied a virtual screening approach to screen the most suitable and drug-able chemical compounds to be used as potential drug targets against T2DM. We have found that out of 5000 chemical compounds that we have analyzed, only two are known to be more effective as per our experiments based upon molecular docking studies and virtual screening through Lipinski's rule and ADMET properties.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Impaired myocardial 18F-FDG uptake correlates with reduced level of hexokinase II but not GLUT4 expression in a rat model of type 2 diabetes mellitus
    Kaiser, Franz
    Pelzer, Theo
    Kreissl, Michael
    Higuchi, Takahiro
    Arias-Loza, Paula
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54
  • [42] Orange Peel Extract and Physical Exercise Synergistically Ameliorate Type 2 Diabetes Mellitus-Induced Dysmetabolism by Upregulating GLUT4 Concentration in Male Wistar Rats
    Olayaki, Luqman Aribidesi
    Okesina, Kazeem Bidemi
    Jesubowale, Jesugbemi Daniel
    Ajibare, Ayodeji Johnson
    Odetayo, Adeyemi Fatai
    JOURNAL OF MEDICINAL FOOD, 2023, 26 (07) : 470 - 479
  • [43] The promoter region of the CTLA4 gene is associated with type 1 diabetes mellitus
    Lee, YJ
    Lo, FS
    Shu, SG
    Wang, CH
    Huang, CY
    Liu, HF
    Wu, CC
    Yang, TY
    Chang, JG
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2001, 14 (04): : 383 - 388
  • [44] GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients - Is insulin resistance in type 2 diabetes a slow, type 1 fiber disease?
    Gaster, M
    Staehr, P
    Beck-Nielsen, H
    Schroder, HD
    Handberg, A
    DIABETES, 2001, 50 (06) : 1324 - 1329
  • [45] 4-Hydroxyisoleucine: A Potential New Treatment for Type 2 Diabetes Mellitus
    Mohammad Ishraq Zafar
    Feng Gao
    BioDrugs, 2016, 30 : 255 - 262
  • [46] 4-Hydroxyisoleucine: A Potential New Treatment for Type 2 Diabetes Mellitus
    Zafar, Mohammad Ishraq
    Gao, Feng
    BIODRUGS, 2016, 30 (04) : 255 - 262
  • [47] Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
    Dave, Darshan J.
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2011, 2 (04) : 230 - 235
  • [48] Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
    Shubrook, Jay
    Colucci, Randall
    Guo, Aili
    Schwartz, Frank
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2011, 4 : 1 - 12
  • [49] Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Neumiller, Joshua J.
    Campbell, R. Keith
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (18) : 1515 - 1525
  • [50] Linagliptin: The Newest Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Aletti, Rachael
    Cheng-Lai, Angela
    CARDIOLOGY IN REVIEW, 2012, 20 (01) : 45 - 51